|View printer-friendly version|
PACE has 250 centers located in 31 States serving a growing number of eligible
“CareKinesis has always offered reminder packaging to our PACE clients, in addition to using our proprietary medication risk mitigation tools to identify the most appropriate and safest administration schedule for each individual,” said TRHC President
“MedaCube is the leading product for elder care home-based medication management. Our mission and culture is perfectly aligned with CareKinesis,” said PharmAdva CEO
As part of its mission to improve medication safety for PACE, CareKinesis is exclusively offering MedaCube to PACE and similar at-risk provider organizations that need help improving adherence and reducing homecare queuing expenditures when adherence packaging is no longer applicable.
“Some PACE participants need additional support with their medications over time,” explained Dr. Knowlton. “Taking the right medications at the right time is key to medication safety and to avoiding preventable ER visits and hospitalizations that put elderly participants at risk for complications. Our PACE clients’ experiences thus far have shown fewer homecare visits for medication adjustment, which results in lower costs for them. Initial client clinical outcomes and satisfaction outcomes are very positive, as well.”
MedaCube is a 10-inch, cube-shaped device that provides real-time notifications to caregivers and nurses when patients do not take medications as expected. If a patient misses a dose or the machine sensors indicate tampering, caregivers/nurses are alerted. CareKinesis provides 24-hour customer service for clients.
CareKinesis partners with healthcare organizations to provide personalized medication therapy management and pharmacy services for high-risk populations. The results are enhanced medication-related outcomes and greater operational efficiency.
PharmAdva develops and offers MedaCube, the only comprehensive medication adherence solution designed and patented by a leading health system (URMC). MedaCube also is the sole product proven under IRB in a peer-reviewed published pharmacy school trial to take patients averaging 50% compliant to a consistent 97% adherence rate. MedaCube is provided by health plans (pilot proven ROI), pharmacies, and providers to their patients, and has
This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the
Bob East or Asher Dewhurst